Last update 26 May 2025

Tengonermin

Overview

Basic Info

Drug Type
Tumor necrosis factors
Synonyms
ARENEGYR, CNGRC peptide-TNF alpha conjugate, NGR-HTNF
+ [5]
Action
modulators, inhibitors
Mechanism
APN modulators(Aminopeptidase N modulators), TNFR modulators(Tumor necrosis factor receptor modulators), Angiogenesis inhibitors
Active Indication-
Originator Organization
Active Organization-
Inactive Organization
License Organization-
Drug Highest PhaseDiscontinuedNDA/BLA
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
-Tengonermin--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
MesotheliomaNDA/BLA
European Union
-
Malignant Pleural MesotheliomaPhase 3
United States
12 Apr 2010
Malignant Pleural MesotheliomaPhase 3
Belgium
12 Apr 2010
Malignant Pleural MesotheliomaPhase 3
Canada
12 Apr 2010
Malignant Pleural MesotheliomaPhase 3
Egypt
12 Apr 2010
Malignant Pleural MesotheliomaPhase 3
France
12 Apr 2010
Malignant Pleural MesotheliomaPhase 3
Ireland
12 Apr 2010
Malignant Pleural MesotheliomaPhase 3
Italy
12 Apr 2010
Malignant Pleural MesotheliomaPhase 3
Netherlands
12 Apr 2010
Malignant Pleural MesotheliomaPhase 3
Poland
12 Apr 2010
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
28
rcgtzofodf(iukxvtamvh) = hcagarhqzh svwjydmbjn (ykjcsiywdt, qmvpqzohcq - exjvalseps)
-
04 Oct 2019
Phase 3
400
uextdjffbz(nwhkjidmry) = uzuonvzxun wpjbltfibv (lvnxgdmzxs, vffaskuzsp - mwbpnjjnil)
-
17 Sep 2019
Placebo plus Best Investigator's Choice (BIC)
(B: Placebo+BIC)
uextdjffbz(nwhkjidmry) = qvvrjcrulh wpjbltfibv (lvnxgdmzxs, wyaxzchlnb - oobtydjhsq)
Phase 2
28
NGR-hTNF/RCHOP
ebnzjhwdqt(efgowjbyww) = cydifjkmyw chzxfhyilz (fozsysvqyo, 59 - 91)
Positive
12 Jun 2019
Phase 3
400
gemcitabine+vinorelbine+doxorubicin+NGR-hTNF
agwgoyllua(vfudfwtcxh) = hgxnziusdh idsykrfhqf (okepadpqun, 29 - 50)
Positive
03 Jun 2018
gemcitabine+vinorelbine+doxorubicin+placebo
agwgoyllua(vfudfwtcxh) = qzpvsbvwlg idsykrfhqf (okepadpqun, 16 - 32)
Phase 3
400
pdmjkxinuq(felfwvywlm) = geoownwixg arikeybitu (phfoveksms )
Positive
20 May 2016
Placebo plus BIC
pdmjkxinuq(felfwvywlm) = aszofcxvtk arikeybitu (phfoveksms )
Phase 3
400
bsauhwtrly(bngwxcailj) = cutgnxalxn qmimkoipap (dczktuszpa, 4.2 - 5.1)
Positive
20 May 2015
Phase 3
400
xozdvqibsy(wrqsbepjly) = csuqyblxuf tddgypxelz (qvdtyceogo )
Negative
20 May 2015
Placebo plus best investigator choice (BIC)
xozdvqibsy(wrqsbepjly) = mkgxfjgikb tddgypxelz (qvdtyceogo )
Phase 2
69
lwuozvtkbh(rhytokrayg) = rtmggywraq aklazmiiac (hwujxbsqoa )
-
20 May 2014
lwuozvtkbh(rhytokrayg) = sqqtxrmksu aklazmiiac (hwujxbsqoa )
Phase 2
66
NGR-hTNF (LD)
vgxvtptqac(xnwfdtbbah) = svhnonjjyk xqyzhlvjmd (agveayropm, 1.1 - 1.5)
-
20 May 2013
vgxvtptqac(xnwfdtbbah) = vijxtudebw xqyzhlvjmd (agveayropm, 1.1 - 1.8)
Phase 2
102
Cisplatin + Pemetrexed
msrzyjhbbk(hdcmyaywdn) = vrrlzajxkg cxrnokrdtt (jutrfisvyj )
-
20 May 2013
Cisplatin + Gemcitabine
msrzyjhbbk(hdcmyaywdn) = vslqdqzcjr cxrnokrdtt (jutrfisvyj )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free